A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer

Abstract Lung cancer remains the leading cause of cancer deaths worldwide. Although low-dose spiral computed tomography (LDCT) screening is used for the detection of lung cancer in a high-risk population, false-positive results of LDCT remain a clinical problem. Here, we developed a blood test of a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bing Wei, Fengxin Wu, Wenqun Xing, Haibo Sun, Chi Yan, Chengzhi Zhao, Dongqing Wang, Xiaobing Chen, Yanli Chen, Mingming Li, Jie Ma
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8541ccf271504b21b2b6ac9441c1c0c9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8541ccf271504b21b2b6ac9441c1c0c9
record_format	dspace
spelling	oai:doaj.org-article:8541ccf271504b21b2b6ac9441c1c0c92021-12-02T16:45:41ZA panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer10.1038/s41598-021-96242-62045-2322https://doaj.org/article/8541ccf271504b21b2b6ac9441c1c0c92021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96242-6https://doaj.org/toc/2045-2322Abstract Lung cancer remains the leading cause of cancer deaths worldwide. Although low-dose spiral computed tomography (LDCT) screening is used for the detection of lung cancer in a high-risk population, false-positive results of LDCT remain a clinical problem. Here, we developed a blood test of a novel panel of three established lung cancer methylation biomarkers for lung cancer detection. Short stature homeobox 2 gene (SHOX2), ras association domain family 1A gene (RASSF1A), and prostaglandin E receptor 4 gene (PTGER4) methylation was analyzed in a training cohort of 351 individuals (197 controls, 154 cases) and validated from an independent cohort of 149 subjects (89 controls, 60 cases). The novel panel biomarkers distinguished between malignant and benign lung disease at high sensitivity and specificity: 87.0% sensitivity [95% CI 80.2–91.5%], 98.0% specificity [95% CI 94.9–99.4%]. Sensitivity in adenocarcinoma, squamous cell carcinoma, small cell lung cancer, and other lung cancer was 89.0%, 87.5%, 85.7%, and 77.8%, respectively. Notably, cancer patients in stage I and II showed high diagnostic sensitivity at 82.5% and 90.5%, respectively. Moreover, the diagnostic efficiency did not show bias toward age, gender, smoking, and the presence of other (nonlung) cancers. The performance of the panel in the validation cohort confirmed the diagnostic value. These findings clearly showed that this panel of DNA methylation biomarkers was effective in detecting lung cancer noninvasively and may provide clinical utility in stand-alone or in combination with current imaging techniques to improve the diagnosis of lung cancer.Bing WeiFengxin WuWenqun XingHaibo SunChi YanChengzhi ZhaoDongqing WangXiaobing ChenYanli ChenMingming LiJie MaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bing Wei Fengxin Wu Wenqun Xing Haibo Sun Chi Yan Chengzhi Zhao Dongqing Wang Xiaobing Chen Yanli Chen Mingming Li Jie Ma A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer
description	Abstract Lung cancer remains the leading cause of cancer deaths worldwide. Although low-dose spiral computed tomography (LDCT) screening is used for the detection of lung cancer in a high-risk population, false-positive results of LDCT remain a clinical problem. Here, we developed a blood test of a novel panel of three established lung cancer methylation biomarkers for lung cancer detection. Short stature homeobox 2 gene (SHOX2), ras association domain family 1A gene (RASSF1A), and prostaglandin E receptor 4 gene (PTGER4) methylation was analyzed in a training cohort of 351 individuals (197 controls, 154 cases) and validated from an independent cohort of 149 subjects (89 controls, 60 cases). The novel panel biomarkers distinguished between malignant and benign lung disease at high sensitivity and specificity: 87.0% sensitivity [95% CI 80.2–91.5%], 98.0% specificity [95% CI 94.9–99.4%]. Sensitivity in adenocarcinoma, squamous cell carcinoma, small cell lung cancer, and other lung cancer was 89.0%, 87.5%, 85.7%, and 77.8%, respectively. Notably, cancer patients in stage I and II showed high diagnostic sensitivity at 82.5% and 90.5%, respectively. Moreover, the diagnostic efficiency did not show bias toward age, gender, smoking, and the presence of other (nonlung) cancers. The performance of the panel in the validation cohort confirmed the diagnostic value. These findings clearly showed that this panel of DNA methylation biomarkers was effective in detecting lung cancer noninvasively and may provide clinical utility in stand-alone or in combination with current imaging techniques to improve the diagnosis of lung cancer.
format	article
author	Bing Wei Fengxin Wu Wenqun Xing Haibo Sun Chi Yan Chengzhi Zhao Dongqing Wang Xiaobing Chen Yanli Chen Mingming Li Jie Ma
author_facet	Bing Wei Fengxin Wu Wenqun Xing Haibo Sun Chi Yan Chengzhi Zhao Dongqing Wang Xiaobing Chen Yanli Chen Mingming Li Jie Ma
author_sort	Bing Wei
title	A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer
title_short	A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer
title_full	A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer
title_fullStr	A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer
title_full_unstemmed	A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer
title_sort	panel of dna methylation biomarkers for detection and improving diagnostic efficiency of lung cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8541ccf271504b21b2b6ac9441c1c0c9
work_keys_str_mv	AT bingwei apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT fengxinwu apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT wenqunxing apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT haibosun apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT chiyan apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT chengzhizhao apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT dongqingwang apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT xiaobingchen apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT yanlichen apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT mingmingli apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT jiema apanelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT bingwei panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT fengxinwu panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT wenqunxing panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT haibosun panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT chiyan panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT chengzhizhao panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT dongqingwang panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT xiaobingchen panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT yanlichen panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT mingmingli panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer AT jiema panelofdnamethylationbiomarkersfordetectionandimprovingdiagnosticefficiencyoflungcancer
_version_	1718383464058716160

A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer

Ejemplares similares